US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

 
• By Urtė Fultinavičiūtė

In a somewhat surprising move, President Trump’s Federal Trade Commission is continuing a crusade to delist improper listings from the FDA’s Orange Book. Law firm Polsinelli’s chair Chad Landmon discussed the impact of the move on the generic drug industry.

Single line drawing of a hand holding golden torch with fire flame.
The FTC continues to send warning letters about potentially improper patent listings in the Orange Book. (Shutterstock)

More from Patents

More from Legal & IP